|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
210 281 | 207 263 | 267 779 | 271 734 | 271 734 | - |
| Entreprise Value (EV)1 |
217 244 | 212 915 | 270 284 | 268 114 | 260 447 | 252 604 |
| P/E ratio |
24,6x | 19,9x | 20,1x | 19,1x | 18,0x | 16,6x |
| Yield |
3,37% | 3,57% | 2,87% | 2,93% | 3,04% | 3,13% |
| Capitalization / Revenue |
3,95x | 3,65x | 4,36x | 4,55x | 4,40x | 4,28x |
| EV / Revenue |
4,08x | 3,75x | 4,40x | 4,49x | 4,22x | 3,98x |
| EV / EBITDA |
10,2x | 9,33x | 10,6x | 10,9x | 10,1x | 9,27x |
| Price to Book |
8,02x | 7,58x | 8,28x | 6,77x | 5,68x | 4,81x |
| Nbr of stocks (in thousands) |
853 263 | 854 163 | 856 061 | 854 642 | 854 642 | - |
| Reference price (CHF) |
247 | 243 | 314 | 317 | 317 | 317 |
| Last update |
02/01/2018 | 01/31/2019 | 01/30/2020 | 01/14/2021 | 01/14/2021 | 01/14/2021 |
|
1 CHF in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
53 299 | 56 846 | 61 466 | 59 737 | 61 728 | 63 442 |
| EBITDA1 |
21 201 | 22 825 | 25 419 | 24 664 | 25 912 | 27 251 |
| Operating profit (EBIT)1 |
19 012 | 20 505 | 22 479 | 21 764 | 22 700 | 24 191 |
| Operating Margin |
35,7% | 36,1% | 36,6% | 36,4% | 36,8% | 38,1% |
| Pre-Tax Profit (EBT)1 |
12 248 | 14 148 | 16 614 | 18 477 | 19 823 | 21 214 |
| Net income1 |
8 633 | 10 500 | 13 497 | 14 623 | 15 413 | 16 594 |
| Net margin |
16,2% | 18,5% | 22,0% | 24,5% | 25,0% | 26,2% |
| EPS2 |
10,0 | 12,2 | 15,6 | 16,6 | 17,6 | 19,0 |
| Dividend per Share2 |
8,30 | 8,70 | 9,00 | 9,28 | 9,61 | 9,92 |
| Last update |
02/01/2018 | 01/31/2019 | 01/30/2020 | 01/15/2021 | 01/15/2021 | 01/15/2021 |
|
1 CHF in Million 2 CHF Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
6 963 | 5 652 | 2 505 | - | - | - |
| Net Cash position1 |
- | - | - | 3 620 | 11 288 | 19 130 |
| Leverage (Debt / EBITDA) |
0,33x | 0,25x | 0,10x | -0,15x | -0,44x | -0,70x |
| Free Cash Flow1 |
13 911 | 14 811 | 16 764 | 15 502 | 16 738 | 18 194 |
| ROE (Net Profit / Equities) |
52,4% | 57,7% | 57,7% | 44,8% | 39,7% | 35,9% |
| Shareholders' equity1 |
16 475 | 18 202 | 23 392 | 32 623 | 38 836 | 46 161 |
| ROA (Net Profit / Asset) |
11,2% | 20,1% | 21,6% | 18,3% | 18,3% | 18,2% |
| Assets1 |
76 747 | 52 252 | 62 621 | 79 829 | 84 348 | 91 076 |
| Book Value Per Share2 |
30,7 | 32,1 | 37,9 | 46,7 | 55,8 | 65,8 |
| Cash Flow per Share2 |
21,0 | 23,2 | 25,9 | 22,7 | 24,1 | 26,2 |
| Capex1 |
3 509 | 4 043 | 3 503 | 4 138 | 4 020 | 4 040 |
| Capex / Sales |
6,58% | 7,11% | 5,70% | 6,93% | 6,51% | 6,37% |
| Last update |
02/01/2018 | 01/31/2019 | 01/30/2020 | 01/15/2021 | 01/15/2021 | 01/14/2021 |
|
1 CHF in Million 2 CHF Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
AstraZeneca shares fall on 'hefty' $39-billion Alexion deal |
Capitalization (CHF) 271 734 261 056 Capitalization (USD) 305 384 588 908 Net sales (CHF) 61 466 000 000 Net sales (USD) 68 934 119 000 Number of employees 97 735 Sales / Employee (CHF) 628 905 Sales / Employee (USD) 705 317 Free-Float capitalization (CHF) 227 123 625 196 Free-Float capitalization (USD) 255 249 575 972 Avg. Exchange 20 sessions (CHF) 660 461 240 Avg. Exchange 20 sessions (USD) 740 707 280 Average Daily Capital Traded 0,24%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
